tiprankstipranks
Trending News
More News >
Repligen Corp (RGEN)
NASDAQ:RGEN
Advertisement

Repligen (RGEN) AI Stock Analysis

Compare
953 Followers

Top Page

RGEN

Repligen

(NASDAQ:RGEN)

Rating:54Neutral
Price Target:
$124.00
▲(1.75%Upside)
Repligen's stock score is primarily driven by a positive earnings call highlighting strategic growth and strong order performance. However, the overall score is tempered by weak financial performance, especially in profitability and valuation concerns due to negative net income. The technical analysis further indicates weak market momentum, underscoring the need for caution.
Positive Factors
Financial Performance
Repligen reported better-than-expected financial results for their 1Q25, with revenues of $169.2 million, up 11.8% year-over-year, and adjusted earnings of $0.39 per share, compared to $0.30 in 1Q24.
Market Position
Repligen is considered a high-growth company in the attractive market of bioprocessing.
Revenue Growth
Repligen has favorably revised its top-line guidance for 2025 to a range of $695M to $720M, up from the prior $685-710M, signaling strong anticipated growth.
Negative Factors
Earnings Forecast
Repligen expects full-year 2025 GAAP net earnings of $0.76 - $0.85 per diluted share, down from the original guidance range of $0.90 - $0.99 per diluted share.
Market Conditions
Uncertainties related to current market and economic conditions could present barriers to achieving positive quarterly earnings comparisons in the near term.
Valuation Concerns
The company's valuation levels are considered a bit rich at this point.

Repligen (RGEN) vs. SPDR S&P 500 ETF (SPY)

Repligen Business Overview & Revenue Model

Company DescriptionRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyRepligen makes money through the sale of its bioprocessing products and technologies to biopharmaceutical companies and CDMOs. The company's revenue model is based on selling consumables and equipment used in the manufacturing of biologic drugs. Key revenue streams include its filtration products, which are used in the purification process, and its chromatography and protein A products, which are essential in the separation and purification of proteins. Repligen's earnings are also supported by strategic partnerships with leading biopharmaceutical companies and a focus on innovation in bioprocessing technologies, which help to ensure a steady demand for its products as the biopharmaceutical industry continues to grow.

Repligen Earnings Call Summary

Earnings Call Date:Apr 29, 2025
(Q1-2025)
|
% Change Since: -15.15%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Positive
Repligen Corporation had a strong start to 2025 with notable achievements in revenue growth, strategic acquisitions, and product launches. However, there are challenges in specific segments such as capital equipment, China, and small biotech companies. Despite these challenges, the company's strategic initiatives and strong order performance indicate a positive outlook for the year.
Q1-2025 Updates
Positive Updates
Strong Organic Revenue Growth
Repligen Corporation reported 11% organic revenue growth for Q1 2025, and 14% growth on an organic non-COVID basis.
Biopharma Revenue Surge
Biopharma revenues reached the highest level ever, excluding COVID, with more than 20% year-over-year growth.
Orders Increase Significantly
Orders were up in the high teens year-over-year, with all franchises growing in double digits.
Strategic Acquisition of 908 Devices' Bioprocessing Portfolio
Repligen acquired 908 Devices' bioprocessing portfolio, aiming to accelerate the digitization of bioprocessing.
Geographical Performance
North America and Europe showed strong growth with 13% increases, while Asia (excluding China) grew by 12%.
Launch of New Products
The company launched the Metanova MixOne, a single-use mixer, and reported positive feedback from the INTERFACE conference.
Negative Updates
Decline in Capital Equipment Revenues
Capital equipment revenues declined year-over-year, although a strong backlog is expected to support growth later in the year.
Challenges in China
Revenue from China continues to decline, now representing only 2% of Q1 2025 revenues.
CDMO Revenue Dip
Contract Development and Manufacturing Organization (CDMO) revenues were down slightly year-over-year.
Small Biotech Sales Decline
Sales to small biotech companies decreased by high single digits, with the segment now representing less than 10% of total business.
Company Guidance
In the first quarter of 2025 earnings call, Repligen Corporation provided guidance for the full fiscal year, maintaining its organic growth expectations despite macroeconomic uncertainties. The company anticipates organic revenue growth between 9.5% to 13.5%, with non-COVID organic growth projected at 11.5% to 15.5%. Repligen also raised its reported revenue guidance to a range of $695 million to $720 million, incorporating the recent acquisition of 908 Devices' bioprocessing portfolio. The firm expects adjusted gross margins between 52% to 53%, reflecting a year-over-year expansion. Repligen highlighted its strategic focus, including innovations like the Metanova mixer and progress in its chromatography and analytics franchises, while successfully navigating potential tariff impacts and foreign exchange headwinds. The company remains optimistic about its opportunities across resilient end markets, emphasizing a strong order backlog and a diversified customer base.

Repligen Financial Statement Overview

Summary
Repligen displays a mixed financial performance with strengths in its balance sheet and operational cash flow, but faces challenges in profitability and growth. The company maintains a strong equity position and low leverage, yet needs to address its declining net income and EBIT margins to improve its financial health and investor confidence.
Income Statement
48
Neutral
Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.
Balance Sheet
65
Positive
The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.
Cash Flow
57
Neutral
Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue634.44M632.36M801.54M670.53M366.26M
Gross Profit274.64M308.83M455.71M391.25M209.63M
EBITDA82.10M127.77M246.93M211.56M101.62M
Net Income-25.51M35.60M185.96M128.29M59.93M
Balance Sheet
Total Assets2.83B2.83B2.52B2.36B1.90B
Cash, Cash Equivalents and Short-Term Investments757.36M751.32M623.76M603.81M717.29M
Total Debt686.25M711.80M422.96M366.05M275.42M
Total Liabilities856.95M866.34M613.96M608.29M373.74M
Stockholders Equity1.97B1.97B397.27M1.75B65.77M
Cash Flow
Free Cash Flow142.49M74.93M38.74M47.74M36.28M
Operating Cash Flow175.39M113.92M172.08M119.02M62.63M
Investing Cash Flow-86.38M-123.28M-233.24M-221.17M-201.38M
Financing Cash Flow-82.90M248.96M-13.34M961.00K305.92M

Repligen Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price121.87
Price Trends
50DMA
124.09
Negative
100DMA
130.37
Negative
200DMA
139.85
Negative
Market Momentum
MACD
-2.15
Positive
RSI
48.94
Neutral
STOCH
33.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Neutral. The current price of 121.87 is below the 20-day moving average (MA) of 123.37, below the 50-day MA of 124.09, and below the 200-day MA of 139.85, indicating a bearish trend. The MACD of -2.15 indicates Positive momentum. The RSI at 48.94 is Neutral, neither overbought nor oversold. The STOCH value of 33.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RGEN.

Repligen Risk Analysis

Repligen disclosed 41 risk factors in its most recent earnings report. Repligen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Repligen Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$6.93B51.519.08%<0.01%2.84%-11.34%
67
Neutral
$3.18B-4.62%7.19%-56.19%
66
Neutral
$5.03B41.729.16%8.24%18.54%
63
Neutral
$5.13B36.953.48%1.17%0.29%-48.98%
61
Neutral
$8.75B116.65-23.93%-0.12%-713.82%
54
Neutral
$6.85B-1.16%4.88%-196.93%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RGEN
Repligen
121.87
-18.92
-13.44%
ICUI
ICU Medical
129.19
1.16
0.91%
MASI
Masimo
161.38
52.39
48.07%
MMSI
Merit Medical Systems
84.22
-1.30
-1.52%
TFX
Teleflex
116.20
-102.26
-46.81%
STVN
Stevanato Group
27.95
8.40
42.97%

Repligen Corporate Events

Executive/Board ChangesShareholder Meetings
Repligen Holds Annual Shareholders Meeting, Key Decisions Made
Neutral
May 15, 2025

On May 15, 2025, Repligen Corporation held its Annual Meeting of Shareholders, where several key decisions were made. The shareholders elected ten directors to the board, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved the compensation of the company’s executive officers, and sanctioned an amendment to the Certificate of Incorporation to limit the liability of certain officers. These decisions are expected to influence Repligen’s governance and operational strategies moving forward.

The most recent analyst rating on (RGEN) stock is a Buy with a $225.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025